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Purpose of Review: Polysubstance use is common, particularly among some age groups and 
sub-cultures. It is also associated with elevated risk of psychiatric and physical health 
problems. We review recent research findings, comment on changes to polysubstance 
diagnoses, report on contemporary clinical and epidemiological polysubstance trends, and 
examine the efficacy of preventive and treatment approaches. 
 
Recent Findings: Approaches to describing polysubstance use profiles are becoming more 
sophisticated. Models over the past 18 months that employ Latent Class Analysis typically 
report a no use or limited range cluster (alcohol/tobacco/marijuana), a moderate range 
cluster (limited range, plus amphetamine derivatives) and an extended range cluster 
(moderate range, plus nonmedical use of prescription drugs and other illicit drugs). 
Prevalence rates vary as a function of the population surveyed. Wider-ranging 
polysubstance users carry higher risk of comorbid psychopathology, health problems and 
deficits in cognitive functioning. 
 
Summary: Wide-ranging polysubstance use is more prevalent in sub-cultures such as 
‘ravers’ (dance club attendees), and those already dependent on substances. Health risks 
are elevated in these groups. Research into prevention and treatment of polysubstance use 
is underdeveloped. There may be benefit in targeting specific polysubstance use and/or risk 
profiles in prevention and clinical research.  
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Key Points 
 Polysubstance use is common, as evidenced by recent epidemiological and clinical 
studies.  
 Wider-ranging polysubstance use is associated with poorer health outcomes. 
 Research into polysubstance prevention requires stronger methodological designs. 
 Targeting specific polysubstance use and/or risk profiles may be effective in future 
clinical and prevention research. 
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INTRODUCTION AND DEFINITIONS 
The term polysubstance use broadly describes the consumption of more than one drug over 
a defined period, simultaneously or at different times for either therapeutic and/or 
recreational purposes. In substance use prevention and treatment, it usually refers to 
multiple illicit drug use, but it can also include licit and prescription medication used for 
non-medical purposes.  
 
Diagnostically, there have been some changes since the introduction of the 5th edition of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM–5) [1*] that relate to the 
substance use disorder spectrum, and polysubstance dependence specifically. 
Polysubstance Dependence has been removed from DSM-5. It was historically diagnosed by 
use of three or more substances (excluding caffeine and nicotine) with no single substance 
dominating. Key to diagnosis was the lack of a specific drug preference, with the primary 
motivation for use being uninterrupted intoxication. Dependence criteria also needed to be 
met for substances as a group, but not for any individual substance. The diagnostic terms of 
Abuse and Dependence for all substances have also been removed from DSM-5 based on 
evidence for unidimensionality of diagnostic criteria [2*]. The non-dichotomised diagnosis 
term Substance Use Disorders is now represented on a continuum of severity ranging from 2 
‘mild’ to 11 ‘severe’. Patients who use multiple substances will be diagnosed by substance 
type, and graded on this scale. This subtle change means that the relatively small but 
clinically unique group of patients who previous DSM Polysubstance Dependence criteria, 
will now be subsumed into a broader diagnostic umbrella. This may have implications from 
a comparative, epidemiological standpoint- although most population level research has not 
included diagnostic criteria or severity, only frequency of substance use. The prospective 
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clinical implications are not yet known. Nor is the reliability of clinical assessments of the 
DSM-5 severity index.  
 
This review examines key polysubstance use research, published predominately over the 
past 18 months. Studies thematically cluster around using innovative statistical methods to 
describe polysubstance trends, recent evidence of psychiatric and physical health risks for 
multiple substance users, and advances in imaging and neuropsychological research on 
polysubstance users. We also review evidence for prevention and treatment, and 
recommend how recent research could be integrated to maximise efficacy of prevention 
and treatment approaches to polysubstance use.  
 
REASONS FOR USE 
There are many reasons why some people choose to use multiple rather than single 
substances. It can be to enhance effects, by combining drugs with similar Central Nervous 
System (CNS) mechanisms such as alcohol and benzdiazapines [3] or two or more anxiolytic-
hypnotics [4]. Drugs with different CNS actions may also be combined to accentuate the 
perceived benefits of each substance, for example opioids/benzodiazepines [5,6,7], 
stimulants/opioids [8] and stimulants/hallucinogens [9].  
 
Substances are used simultaneously or sequentially to ameliorate the adverse effects of 
drug craving or withdrawal. For example, stimulants are used to overcome dysphoria, and 
CNS depressants such as benzodiazepines, to manage withdrawal symptoms of anxiety and 
agitation. Opportunistic access, experimentation and conformity to subculture substance 
use norms are also motivators for multiple drug use. Substance users can be proficient at 
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assessing the cost/benefit ratios of drug effects, and their use is frequently driven my 
market forces. The well documented reduction in the availability of heroin in Australia (circa 
2000) saw heroin use increasingly supplemented with amphetamines [10]. As with other 
drug use, polysubstance use is more common among socioeconomic disadvantage [11]. It is 
especially common in some sub-cultures such as ‘ravers’ (dance club attendees), with recent 
reports of up to 75% using multiple substances, with on average five drugs used at the last 
rave attended [12]. Opportunistic and experimental drug use can establish powerful positive 
drug outcome expectancies that reinforce ongoing use and elevate risk of dependence [13]. 
 
There has been increased media interest [14] in the combined use of caffeine (in the form of 
‘energy’ drinks) and alcohol, reportedly to extend and enhance intoxication. Short-term 
behavioural effects and perceived levels of elevated synergistic intoxication have not been 
found in experimental studies using low doses of caffeine and alcohol [15*,16*]. Further 
research independent of industry funding is recommended to validate the short and longer 
term risks of the higher doses of alcohol and energy drinks typically consumed in real world 
settings [17**].  
 
PREVALENCE AND CURRENT PATTERNS OF MULTIPLE SUBSTANCE USE 
In 2013, large scale survey research on polysubstance use was conducted in the US 
[18**,19*,20**], UK [21**], Australia [22**,23**], Denmark [24**], and Latin American 
countries [25**,26**,27**]. Operationalizations of polysubstance use have typically been 
based on lifetime prevalence [23**,24**,26**,18**], 1-12 month prevalence 
[21**,19*,27**,20**,25**,26**,22**], and simultaneous polysubstance use (multiple 
substances used on the same occasion) [26**,22**]. There have been challenges in 
7 
 
 
capturing simultaneous polysubstance use, because respondents could not be specifically 
asked about all of the often-large number of combinations of drug-pairs. Simultaneous 
polysubstance use has been most frequently assessed in smaller studies of high-risk 
populations, including club/bar patrons [28*] and clinical/subclinical populations [29*, 30*].  
 
Latent Class Analysis (LCA) analyses of a comprehensive range of drugs reveal that uses fall 
into a small number of clusters of increasing drug involvement. These included: a limited 
range cluster (who use alcohol/tobacco/marijuana); a moderate range cluster (in which 
amphetamine derivatives are added) and an extended range cluster (in which the 
nonmedical use of prescription drugs, and other illicit drugs is added) [22**,24**,31,23**]. 
 
Since 2013, there has been more research on polysubstance use in teen populations 
[20**,27**,25**,23**,18**] and young adults [26**,19*,24**,21**,22**]. Amongst 
teenagers, polysubstance use was most commonly limited in range [23**,18**] but the 
prevalence of use was high. Between 18% (lifetime prevalence in 12-17 year olds; [23**] 
and 34% (prior to age 16; [18**]) of teenagers report limited range polysubstance use. 
These findings suggest that use of certain drugs may occur in the context of other drug use 
(e.g., alcohol use increases the risk of experimentation with smoking; [32]). Research on 
simultaneous polysubstance use in this age group is needed to clarify the extent to which 
this occurs. In older groups, those who report polysubstance use in the last 12 months are 
also very likely to report simultaneous use [22**]. 
 
Non-medical prescription drug use (NMPDU) has gained recent attention. In the US National 
Survey on Drug Use and Health [33], 6.3% (> 12 years) reported NMPDU in the past year, 
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and 2.7% reported NMPDU use in the past month. Prevalence rates were 4.8% for pain 
relievers, 2.1% for tranquilizers, 1.2% for stimulants, and 0.3% for sedatives. Rates were 
higher in those aged 18-25 years (14.4-15.5% for past year) than in 12-17 year olds (7.8-
8.7%) and those aged 26 years and older (3.8-4.8%). In a Nationally representative sample of 
US high school seniors (modal age 18 years), life time prevalence of non-medical 
benzodiazepines use was 7.5% [34]. Nonmedical users of prescription opioids have higher 
rates of alcohol and illegal drug use than medical prescription drug users and nonusers 
[35*,36*,37]. There is some evidence that polysubstance use involving NMPDU is higher in 
young adult women than men [26**,19*]. In Australia, a nationally representative survey 
data revealed a small but distinct cluster of young adults who engaged in sedative and 
alcohol use (past year prevalence, 1.3%) [22**]. 
 
Limited range polysubstance use in adolescence may increase the risk of expanded 
polysubstance use in young adulthood. Panel survey designs show that in the teen years 
(12-17 years), extended range polysubstance use is comparatively rare (2%), but is much 
higher (13.5%) in the 18-29 age group [22**,23**]. In research that retrospectively assesses 
early polysubstance use, limited range polysubstance use is associated with later drug use, 
including NMPDU [18**]. Young adult males (around 18-35 years) are at elevated risk of 
extended polysubstance use [26**,22**,27**,38]. Other correlates include being single, low 
education, and being employed [21**,22**]. Expansion of polysubstance use to include 
amphetamine derivatives and cocaine is often associated with reaching the legal age for 
club/dance attendance. In club/dance venues, polysubstance use is widespread [25**] and 
prevalence rates are far higher than in other venue types [28*].  
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COMORBID PSYCHOPATHOLOGY AND HEALTH 
Latent Class Analyses (LCA) show that those reporting use of wide ranging multiple 
substances have poorer mental health than those that use no or few substances. For 
example, they report higher levels of general psychological distress [23**,22**] and more 
symptoms of anxiety and depression [31]. Alcohol users that are classified by LCA as having 
concurrent illicit drug use are more likely to have generalized anxiety and major depressive 
disorders [39]. In a treatment seeking, cannabis using population, wide-ranging substance 
users identified by LCA had higher levels of depression, anxiety, manic-excitement and more 
positive psychotic symptoms than patients who used no other illicit substances [40]. LCA 
studies have also identified elevated sexual risk behaviours, and infectious disease 
prevalence among polysubstance users [41,42]. Polysubstance use is especially prevalent in 
treatment seeking substance abusers [43], sexual health high risk populations including men 
who have sex with men (MSM) [44], HIV infected MSM [45] and transgender women [46]. 
 
A number of recent studies and reviews have reminded the health community of the often 
under recognised dangers of combining benzodiazepines and opiates for recreational use, or 
to manage chronic pain [47*,6,7]. In a large national Danish sample [6], long term opiate 
users with chronic pain carried a 27 times higher odds ratio (95% CI 14.85–49.15) of long-
term use of benzodiazepines abuse than individuals without chronic pain. It is not entirely 
clear why patients with chronic pain are more likely to abuse opiates with benzodiazepines. 
A recent review [7] suggests that recreational consumption of benzodiazepines is the 
primary motivation, rather than previously documented self-medication hypotheses. 
Regardless of the motivations for use, patients who use both benzodiazepines and opioids 
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are at higher risk of non-fatal and fatal overdoses [47*], comorbid mental and physical 
conditions, and forensic problems [7]. 
 
IMAGING AND NEUROPSYCHOLOGY STUDIES 
Imaging studies suggest that the abuse of multiple substances may have a cumulative or 
synergistic adverse effect on brain function and neurocognition [48]. Abstinent 
polysubstance abusers have reduced gray matter in the right temporal pole and medial 
frontal lobe, including the superior, cingulate and para-cingulate gyri [49*]. Abe and 
colleagues [50**] employed high field brain magnetic resonance spectroscopy to study 
differences in brain metabolite concentrations in polysubstance abuse. Polysubstance 
abusers were defined as meeting DSM-IV criteria for dependence on alcohol in addition to 
one or more psychostimulants (mostly cocaine). At 1-month abstinence, polysubstance 
abusers had significantly lower concentrations of N-acetylaspartate, creatine, myo-Inositol, 
and choline-containing metabolites in the dorsolateral prefrontal cortex than alcohol-
dependent individuals, who did not differ from healthy controls. Among polysubstance 
abusers, levels of N-acetylaspartate metabolites in this region were strongly correlated with 
deficits in visuospatial and working memory performance. This suggests that long-lasting 
memory deficits in polysubstance abusers may be the result of persistent abnormalities in 
neuronal integrity. Myo-Inositol abnormalities have been detected in the temporal cortex, 
cerebellar vermis, and lenticular nucleus, but these were not associated with cognitive 
performance [51] In neither of the studies were these abnormalities related to severity of 
consumption.  
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The relationships between brain function and drug doses may differ according to age, the 
substances abused, or how ‘dose’ is measured. Dose-related abnormalities in frontal N-
acetylaspartate have been reported in adolescent polysubstance abusers compared to 
cannabis-dependent individuals and controls, suggesting a greater vulnerability to 
neurotoxicity in younger polysubstance users [52]. Dose-related alterations in cortical 
serotonin signalling have also been observed in long-term abstinent polysubstance users, 
but these were specific to MDMA, suggesting a unique role in serotonin neurotoxicity [53]. 
Other studies have shown dose-dependent associations between MDMA and brain activity 
in the parahippocampal gyrus and superior parietal lobule during memory encoding but not 
retrieval [54,55]. However, these studies, and other recent investigations of inhibitory 
control [56] and decision-making [57], find no difference in behavioural performance 
between polysubstance abusers and controls. This contrasts with the body of 
neuropsychological evidence of impairments resulting from substance abuse [58,59]. 
 
Some have interpreted the discrepancy between neural and behavioural outcomes as 
reflecting the engagement of compensatory processes to achieve equivalent performance 
[56,55]. It is also possible that neuropsychological tasks adapted and simplified for the 
scanner lack sensitivity or that neuroimaging studies lack sufficient sample sizes for 
adequate statistical power [60]. Large differences have been reported in behavioural 
performance between polysubstance abusers and controls on standardized 
neuropsychological tests of working memory, inhibition, cognitive flexibility, self-regulation 
and decision-making (administered outside the scanner [61]). Test performance correlated 
with resting brain metabolism in the right middle temporal pole (working memory), right 
calcarine and bilateral posterior cingulate (self-regulation), and right middle and superior 
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frontal cortices (decision-making). However, only severity of cocaine use was related to 
brain metabolism (right middle temporal pole). Therefore, while polysubstance abuse is 
clearly associated with deficits in brain function and cognition, elucidating more specific 
relationships is made difficult by methodological differences between studies, differences in 
the wide range of substances abused and possibly reduced statistical power in 
neuroimaging studies [62*,60]. 
 
PREVENTION, TREATMENT AND FURTHER RESEARCH  
Prevention programs delivered in schools and community to reduce youth substance use 
generally demonstrate modest efficacy, with some studies showing small short-term effects, 
but poor longer term outcomes [63,64,65]. When prevention programs that specifically 
target adult polysubstance users are reviewed, pervasive methodological weaknesses 
prevent strong conclusions being drawn about efficacy [66]. Psychological treatments for 
alcohol, cannabis, tobacco and amphetamine are effective in reducing severity of disorders, 
as are pharmacological approaches to opiate, nicotine and alcohol dependence [67]. There 
is currently limited evidence to assess whether treating multiple substance problems 
concurrently is more effective than treating them individually and sequentially.  
 
There is an intuitive appeal for targeting prevention and treatment approaches based on 
individual risk profiles [68,69,70]. Some promising prevention results targeting personality 
risk have recently been reported at 24 months follow-up [71*]. Future research may 
consider if specific types of polysubstance clusters, as identified in the current review, 
respond better to targeted prevention and treatment approaches.  
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Future epidemiological research needs to move beyond binary measures of drug use to 
polysubstance use profiles that incorporate measures of frequency/severity 
[40,19*,38,18**]. The could also explore longitudinal transitions in patterns of 
polysubstance use, particularly between ages 14 and 35, where polysubstance use 
frequently develops, peaks and subsides [27**,26**,25**]. The increased use of Latent 
Class Analysis and Latent Transition Analysis [20**] will help identify patterns of both 
‘forward’ and ‘backward’ transitioning (widening/narrowing of drug types). These statistical 
technologies may be helpful in determining timings for prevention targets for specific drug 
types and combinations of drugs. 
 
It is clear that individuals who use multiple substances are at elevated risk of developing 
comirbid psychiatric and other health conditions. They also have more pervasive deficits in 
cognitive functioning that place them at elevated risk of poorer treatment outcomes. 
Prevention and treatment approaches for polysubstance use are underdeveloped by 
comparison with treatments for abuse of single substances. Future research will tell what 
effects removing Polysubstance Dependence from DSM-5 will have on the identification and 
treatment of this group of substance users. 
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